



KEMENTERIAN PERDAGANGAN DALAM NEGERI
DAN HAL EHWAL PENGGUNA MALAYSIA,
BAHAGIAN HARTA INTELEK,
TINGKAT 27, 30 DAN 32,
MENARA DAYABUMI,
JALAN SULTAN HISHAMUDDIN,
50623 KUALA LUMPUR

*Ministry of Domestic Trade and Consumer Affairs Malaysia,
Intellectual Property Division*

*Telefon: 03-2741000
Fax: 2741332*

Fail Tuan:

Fail Kita:

Tarikh:

To:



Dr. Margaret Chai Sook Yin

SIRIM BHD. Persiaran Dato' Menteri,

P.O. Box 7035 Section 2

40911 Shah Alam

MALAYSIA

PATENT APPLICATION NO: PI 2000 4837

This is to certify that annexed hereto is a true copy from the records of the Registry of Trade Marks and Patents, Malaysia of the application as originally filed which is identified therein.

By authority of the
REGISTRAR OF PATENTS

ABDUL RAHMAN RAMLI
(CERTIFYING OFFICER)

15 August 2001



KEMENTERIAN PERDAGANGAN DALAM NEGERI
DAN HAL EHWAL PENGGUNA MALAYSIA
BAHAGIAN HARTA INTELEK,
TINGKAT 27 & 32,
MENARA DAYABUMI,
JALAN SULTAN HISHAMUDDIN,
50623 KUALA LUMPUR.
*Ministry of Domestic Trade and Consumer Affairs Malaysia
Intellectual Property Division.*


*Telefon : 03-22742100
Fax : 03-22741332*

CERTIFICATE OF FILING

APPLICANT : UNIVERSITI PUTRA MALAYSIA
APPLICATION NO. : PI 20004837
REQUEST RECEIVED ON : 16/10/2000
FILING DATE : 16/10/2000
AGENT'S/APPLICANT'S : ISD 426/13/1 [EPD/2000-5/27]
FILE REF.

Please find attached, a copy of the Request Form relating to the above application, with the filing date and application number marked thereon in accordance with Regulation 25(1).

Date : 20/10/2000


.....
(Hasnon Bt. Alang Mohd Rashid)
for Registrar of Patents

To : DR. MARGARET CHAI SOOK YIN,
SIRIM BERHAD,
1, PERSIARAN DATO' MENTERI,
SEKSYEN 2, P.O BOX 7035,
40911 SHAH ALAM,
SELANGOR DARUL EHSAN,
MALAYSIA.

III. INVENTOR

Applicant is the inventor

Yes

☐

No

☒

If the applicant is not the inventor :

Name of inventor s:

1. Prof. Madya Datin Dr. Khatijah Yusoff

2. Dr. Tan Wen Siang

3. Cik Kho Chiew Ling

Address of inventors :

Jabatan Biokimia dan Mikrobiologi,

Fakulti Sains dan Pengajian Alam Sekitar,

Universiti Putra Malaysia,

UPM 43400 Serdang, Selangor.

A statement justifying the applicant's right to the patent accompanies this Form :

Yes

☒

No

☐

Additional Information (if any)

IV. AGENT OR REPRESENTATIVE

Applicant has appointed a patent agent in accompanying Form No. 17

Yes

☒

No

☐

Agent's Registration No. : (PA/2000/0099)

Applicants have appointed
To be their common representative

V. DIVISIONAL APPLICATION

This application is a divisional application

☐

The benefit of the

filing date

priority date

☐

of the initial application is claimed in as much as the subject-matter of the present application is contained in the initial application identified below :

Initial Application No. :

Date of filing of initial application :

VI. DISCLOSURE TO BE DISREGARDED FOR PRIOR ART PURPOSES

Additional information is contained in supplemental box :

(a) Disclosure was due to acts of applicant or his predecessor in title

☐

Date of disclosure: _____

(b) Disclosure was due to abuse of rights of applicant or his predecessor in title

☐

Date of disclosure: _____

A statement specifying in more detail the facts concerning the disclosure accompanies this Form

Yes

☐

No

☐

Additional Information (If any)

VII. PRIORITY CLAIM (if any)

The priority of an earlier application is claimed as follows :

Country (if the earlier application is a regional or international application, indicate the office with which it is filed) :

Filing Date : _____

Application No. : _____

Symbol of the International Patent Classification :

If not yet allocated, please tick

☐

The priority of more than one earlier application is claimed:

Yes

☐

No

☐

The certified copy of the earlier application(s) accompanies this Form:

Yes


☐

No

☐

If No, it will be furnished by

Additional Information (if any)



VIII. CHECK LIST

A. This application contains the following :

1. request		Sheets
2. description	20	Sheets
3. claim	11	Sheets
4. abstract	1	Sheets
5. drawings	2	Sheets
Total	34	Sheets

B. This Form, as filed, is accompanied by the items checked below :

(a) signed Form No. 17

☒

(b) declaration that inventor does not wish to be named in the patent

☐

(c) statement justifying applicant's right to the patent

☒

(d) statement that certain disclosures to be disregarded

☐

(e) priority document (certified copy of earlier application)

☐

(f) cash, cheque, money order, banker's draft or postal order for the payment of application fee

☒

(g) other documents (specify) Form 5

☒

IX. SIGNATURE

Dr. Margaret Chai Sook Yin
 **(~~Applicant~~/Agent)

14/10/2000
 (Date)

If Agent, indicate Agent's Registration No. : (PA/2000/0099)

For Official Use

1. Date application received :

2. Date of receipt of correction, later filed papers or drawings completing the application :

* Delete whichever does not apply

** Type name under signature and delete whichever does not apply

Nucleotide Sequences of the Nucleocapsid (NP) and Phosphoprotein (P) Genes of a Malaysian Velogenic Newcastle Disease Virus Strain AF2240 and the Production of the NP and P Proteins in *Escherichia coli*

Field of the Invention


- 5 The present invention relates to nucleotide sequences encoding the nucleocapsid (NP) protein and phosphoprotein (P) of Newcastle disease virus (NDV) strain AF2240, and the production of the corresponding proteins with recombinant plasmids bearing the nucleotide sequences in *Escherichia coli*.

10 **Description of the Prior Art**

- Newcastle disease virus (NDV) is the prototype of avian paramyxovirus, which causes a highly contagious disease known as Newcastle disease (ND) in many avian species. This disease is of great economic importance requiring control by vaccination or quarantine with slaughter of all birds in confirmed outbreaks, resulting in substantial losses in the poultry industry worldwide. Therefore, development of an improved vaccine and also a rapid and sensitive diagnostic test are greatly desired by the poultry industry.

- A Malaysian heat resistant NDV strain AF2240, which causes 100% mortality in susceptible chicken flocks has been reported by Abdul Rahman *et al.* (1976) and Lai, C.M. (1985). Further studies by Idris *et al.* (1993) revealed that the thermostabilities of haemagglutination and neuraminidase activities of this AF2240 strain were found to be higher than those of other strains. The basis giving rise to these unique features is still unknown. However a comprehensive understanding of the viral proteins would provide some solutions and useful information for the development of heat stable recombinant vaccines and diagnostic tests.

- 25 The genome of NDV is a linear, non-segmented, single-stranded negative sense RNA with a molecular weight of $5.2-5.7 \times 10^6$ Daltons, or approximately 15,000 bases which encodes six main structural proteins. The genomic RNA is associated with the nucleocapsid (NP), phosphoprotein (P) and large (L) proteins. These macromolecules



form the transcriptive complex of the virus, which in turn is surrounded by a lipid bilayer membrane derived from the host cell. Embedded in the membrane are the haemagglutinin-neuraminidase (HN) and fusion (F) glycoproteins. Beneath the lipid bilayer is a shell of protein known as the matrix (M) protein, which is believed to interact with the transcriptive complex. The HN and F glycoproteins are associated with the host cell receptor during infection. The NP encapsidates the viral RNA together with the L protein which is thought to be the transcriptase, and a P protein with an unknown reason.

The genes encoding for the HN (EMBL/Gen Bank/DDBJ accession No.X70092), F (EMBL/Gen Bank/DDBJ accession No.AFO48763) and M (EMBL/Gen Bank/DDBJ accession No. AF060563) proteins of the NDV strain AF2240 have been completely sequenced by Tan *et al.* (1995), Salih *et al.* (2000) and Jemain, S.F.P. (1999) respectively. From the HN gene sequence of strain AF2240, it was quite clear that this strain is different from the other published NDV strains. The HN protein lacked the Arg (403) residue and contained 581 amino acids. At the time when the project was initiated, there was no information available on the coding sequences for the NP and P proteins of NDV strain AF2240. Therefore it remained a problem to prepare cDNA for the cloning of the NP and P genes of NDV.

The inventors have now successfully determined the nucleotide sequences encoding the NP and P proteins of NDV strain AF2240. The accession numbers for the genes encoding the NP and P proteins are EMBL/Gen Bank/DDBJ No. AF284646 and AF284647 respectively. The inventors had discovered that the proteins, in either non-fusion or fusion forms bearing the *myc* epitope and six residues of His at their carboxyl terminal end could be successfully produced in *E. coli* by means of recombinant DNA technologies. The NP and P proteins were expressed to a substantial level in the bacteria and can be recognised by chicken anti-NDV serum.

Summary of invention

The present invention provides nucleotides encoding the full length NP and P polypeptides of Newcastle disease virus strain AF2240. Whereas the genome of NDV is of length approximately 15,000 nucleotides, it has been determined, by this invention, that the portion coding for the NP polypeptide is approximately 1470 nucleotides long and the

portion that codes for the P polypeptide is approximately 1188 nucleotides long. Accordingly, one aspect of the present invention provides for the coding regions of the nucleocapsid (NP) and phosphoprotein (P) genes of Newcastle disease virus strain AF2240. Both the nucleotide sequences are as listed below:

5 NP coding region

	10	20	30	40	50	60
	ATGTCTTCCG	TATTCGATGA	ATACGAGCAG	CTCCTCGCTG	CTCAGACTCG	CCCCAATGGA
	70	80	90	100	110	120
10	GCTCACGGAG	GGGGAGAGAG	AGGGAGCACT	TTAAGAGTTG	AGGTCCCAGT	ATTCACTCTT
	130	140	150	160	170	180
	AACAGTGACG	ATCCAGAAGA	TAGATGGAAT	TTTGCGGTAT	TCTGTCTTCG	GATTGCTGTT
	190	200	210	220	230	240
	AGCGAGGACG	CCAACAAACC	GCTCAGGCAA	GGTGCTCTCA	TATCCCTCCT	GTGCTCCCAT
	250	260	270	280	290	300
15	TCTCAAGTGA	TGAGGAACCA	TGTTGCCCTT	GCAGGAAAAC	AGAATGAGGC	TACACTGACT
	310	320	330	340	350	360
	GTTCTTGAGA	TCGATGGTTT	TACCAGCAGC	GTGCCTCAGT	TCAACAACAG	GAGTGGGGTG
	370	380	390	400	410	420
20	TCTGAGGAGA	GAGCACAGAG	ATTCATGGTG	ATAGCAGGGT	CTCTCCCTCG	GGCGTGCAGT
	430	440	450	460	470	480
	AACGGTACTC	CGTTCGTCAC	GGCTGGGGTT	GAAGATGATG	CACCAGAAGA	TATCACTGAT
	490	500	510	520	530	540
	ACTCTGGAAA	GAATCCTGTC	TATCCAGGCT	CAGGTATGGG	TCACAGTAGC	GAAGGCCATG
	550	560	570	580	590	600
25	ACTGCAATATG	AGACAGCAGA	TGAGTCGGAA	ACAAGAAGAA	TCAATAAGTA	CATGCAGCAA
	610	620	630	640	650	660
	GGCAGAGTCC	AGAAGAAGTA	CATCCTCCAC	CCTGTATGCA	GGAGTGCAAT	TCAACTCACA

670 680 690 700 710 720
 ATCAGACATT CTCTGGCAGT CCGCATTTTC TTAGTTAGCG AGCTTAAGAG AGGCCGCAAT
 730 740 750 760 770 780
 ACGGCAGGTG GGAGCTCCAC GTATTACAAC TTAGTAGGGG ATGTAGACTC ATACATCAGG
 5 790 800 810 820 830 840
 AACACCGGAC TTA CTG CATT CTT CCTTACA CTC AAATATG GAATTAATAC CAAGACATCA
 850 860 870 880 890 900
 GCCCTAGCAC TCAGCAGCCT CACAGGCGAT ATCCAAAAGA TGAAGCAGCT CATGCGTTTA
 910 920 930 940 950 960
 15 TATCGGATGA AGGGAGAAAA TGCGCCGTAC ATGACATTGC TAGGTGACAG TGATCAGATG
 970 980 990 1000 1010 1020
 AGCTTTGCAC CGGCTGAGTA TGCACAGCTT TATTCTTTTG CCATGGGCAT GGCATCAGTC
 1030 1040 1050 1060 1070 1080
 TTAGATAAAG GAACTGGCAA ATACCAATTC GCCAGAGACT TCATGAGCAC ATCATTCTGG
 1090 1100 1110 1120 1130 1140
 20 AGACTCGGGG TGGAGTATGC TCAGGCTCAG GGGAGTAGCA TCAACGAAGA CATGGCTGCT
 1150 1160 1170 1180 1190 1200
 GAGCTAAAAC TAACCCCGGC AGCAAGAAGG GGCCTGGCAG CTGCTGCCCA ACGAGTGTCT
 1210 1220 1230 1240 1250 1260
 25 GAGGAAACTG GCAGCGTGGA TATTCTACT CAACAAGCCG GGGTCCTCAC TGGGCTCAGC
 1270 1280 1290 1300 1310 1320
 GATGGAGGCC CCCGAGCCTC TCAGGGTGGA TCGAACAAGT CGCAAGGGCA ACCAGATGCC
 1330 1340 1350 1360 1370 1380
 GGAGATGGGG AGACCCAATT CTTGGATTG ATGAGAGCAG TGGCGAACAG CATGCGAGAA
 1390 1400 1410 1420 1430 1440
 30 GCGCCAAACT CCGCACAGAG CACCACCCAC CCGGAACCCC CCCC GACTCC CGGGCCATCA

1450 1460 1470 1480 1490 1500
 CAAGATAACG ACACCGACTG GGGGTATTGA

P gene coding region

5
 10 20 30 40 50 60
 ATGGCCACCT TTACAGATGC GGAGATAGAT GATATATTTG AGACCAGTGG AACTGTCATT

70 80 90 100 110 120
 GACAGCATAA TTACGGCCCA GGGTAAATCA GCAGAGACTG TCGGAAGGAG CGCAATCCCA

130 140 150 160 170 180
 CAAGGCAAGA CCAAAGCGCT GAGCATAGCA TGGGAGAAGC ATGGGAGCAT CCAACCATCC

10
 190 200 210 220 230 240
 ACCAGCCAGG ACAACCCCGA CCAACAGGAT AGACCAGACA AACAGCTATC CACACCTGAG

250 260 270 280 290 300
 CAGGCGACCC CACACAACAG CTCGCCAGCC ACATCCGCCG AACCGTCCC CACTCAGGCC

310 320 330 340 350 360
 15 GCAGGTGAGG CCGGCGACAC ACAGCTCAAG ACCGGAGCAA GCAACTCTCT TCTGTCTATG

370 380 390 400 410 420
 CTCGACAAGC TGAGCAATAA ACCATCTAAT GCTAAAAAGG GCCCATGGTC GAGTCCCCAG

430 440 450 460 470 480
 GAAGGATATC ATCAACCTCC GACCCAACAA CATGGGGATC AGCCGAACCG CGGAAACAGC

20
 490 500 510 520 530 540
 CAGGAGAGGC TGCGGCACCA AGCCAAGGCC GCCCCTGGAA GCCGGGGCAC AGACGCGAGC

550 560 570 580 590 600
 ACAGCATATC ATGGACAATG GAAGGAGTCA CAACTATCAG CTGGTGCAAC CCCTCATGTG

610 620 630 640 650 660
 25 CTCCAATCAG GGCAGAGCCA AGACAGTACT CCTGTACCTG TGGATCATGT CCAGCCACCT

670 680 690 700 710 720
 GTCGACTTTG TGCAGGCGAT GATGACTATG ATGGAGGCGT TATCACAGAA GGTAAGTAAA

```

      730      740      750      760      770      780
GTCGACTATC AGCTAGACCT AGTCTTAAAG CAGACATCCT CCATCCCTAT GATGCGGTCT

      790      800      810      820      830      840
GAAATCCAAC AGCTAAAAAC ATCTGTTGCG GTCATGGAAG CTAATTTAGG CATGATGAAA

5      850      860      870      880      890      900
ATTCTGGACC CTGGTTGTGC TAACATTTCA TCCTTAAGTG ATCTGCGGGC AGTCGCCCCG

      910      920      930      940      950      960
TCCCACCCAG TTTTAATTTT AGGCCCCGGA GATCCGTCCC CCTACGTGAC ACAAGGGGGT

      970      980      990      1000      1010      1020
10 GAGATGACAC TCAATAAACT CTCACAACCA GTACAACACC CTTCCGAGTT AATTAAATCT

      1030      1040      1050      1060      1070      1080
GCCACAGCGG GCGGACCTGA TATGGGAGTG GAAAAGGACA CTGTCCGTGC ATTGATCACC

      1090      1100      1110      1120      1130      1140
TCGCGCCCGA TGCATCCAAG CTCCTCAGCT AAGCTCCTGA GTAAGCTGGA TGCAGCCGGG

15      1150      1160      1170      1180      1190      1200
TCGATTGAAG AGATCAGAAA GATCAAGCGC CTTGCACTAA ATGGCTAA.. .....
```

Further, the present invention provides the amino acid sequences of both the NP and P proteins as listed below:

NP gene: amino acid sequence

```

20      1   M   S   S   V   F   D   E   Y   E   Q   L   L   A   A   Q   T      16
      ATG TCT TCC GTA TTC GAT GAA TAC GAG CAG CTC CTC GCT GCT CAG ACT
      1           10           20           30           40

      17  R   P   N   G   A   H   G   G   G   E   R   G   S   T   L   R      32
      CGC CCC AAT GGA GCT CAC GGA GGG GGA GAG AGA GGG AGC ACT TTA AGA

25      50           60           70           80           90
```

33 V E V P V F T L N S D D P E D R 48
 GTT GAG GTC CCA GTA TTC ACT CTT AAC AGT GAC GAT CCA GAA GAT AGA
 100 110 120 130 140

5 49 W N F A V F C L R I A V S E D A 64
 TGG AAT TTT GCG GTA TTC TGT CTT CGG ATT GCT GTT AGC GAG GAC GCC
 150 160 170 180 190

65 N K P L R Q G A L I S L L C S H 80
 AAC AAA CCG CTC AGG CAA GGT GCT CTC ATA TCC CTC CTG TGC TCC CAT
 200 210 220 230 240

10 81 S Q V M R N H V A L A G K Q N E 96
 TCT CAA GTG ATG AGG AAC CAT GTT GCC CTT GCA GGA AAA CAG AAT GAG
 250 260 270 280

15 97 A T L T V L E I D G F T S S V P 112
 GCT ACA CTG ACT GTT CTT GAG ATC GAT GGT TTT ACC AGC AGC GTG CCT
 290 300 310 320 330

113 Q F N N R S G V S E E R A Q R F 128
 CAG TTC AAC AAC AGG AGT GGG GTG TCT GAG GAG AGA GCA CAG AGA TTC
 340 350 360 370 380

20 129 M V I A G S L P R A C S N G T P 144
 ATG GTG ATA GCA GGG TCT CTC CCT CGG GCG TGC AGT AAC GGT ACT CCG
 390 400 410 420 430

145 F V T A G V E D D A P E D I T D 160
 TTC GTC ACG GCT GGG GTT GAA GAT GAT GCA CCA GAA GAT ATC ACT GAT
 440 450 460 470 480

25 161 T L E R I L S I Q A Q V W V T V 176
 ACT CTG GAA AGA ATC CTG TCT ATC CAG GCT CAG GTA TGG GTC ACA GTA
 490 500 510 520

177 A K A M T A Y E T A D E S E T R 192
 GCG AAG GCC ATG ACT GCA TAT GAG ACA GCA GAT GAG TCG GAA ACA AGA
 530 540 550 560 570

30 193 R I N K Y M Q Q G R V Q K K Y I 208
 AGA ATC AAT AAG TAC ATG CAG CAA GGC AGA GTC CAG AAG AAG TAC ATC
 580 590 600 610 620

5

10

15

20

25

30

209	L H P V C R S A I Q L T I R H S	224
	CTC CAC CCT GTA TGC AGG AGT GCA ATT CAA CTC ACA ATC AGA CAT TCT	
	630 640 650 660 670	
225	L A V R I F L V S E L K R G R N	240
	CTG GCA GTC CGC ATT TTC TTA GTT AGC GAG CTT AAG AGA GGC CGC AAT	
	680 690 700 710 720	
241	T A G G S S T Y Y N L V G D V D	256
	ACG GCA GGT GGG AGC TCC ACG TAT TAC AAC TTA GTA GGG GAT GTA GAC	
	730 740 750 760	
257	S Y I R N T G L T A F F L T L K	272
	TCA TAC ATC AGG AAC ACC GGA CTT ACT GCA TTC TTC CTT ACA CTC AAA	
	770 780 790 800 810	
273	Y G I N T K T S A L A L S S L T	288
	TAT GGA ATT AAT ACC AAG ACA TCA GCC CTA GCA CTC AGC AGC CTC ACA	
	820 830 840 850 860	
289	G D I Q K M K Q L M R L Y R M K	304
	GGC GAT ATC CAA AAG ATG AAG CAG CTC ATG CGT TTA TAT CGG ATG AAG	
	870 880 890 900 910	
305	G E N A P Y M T L L G D S D Q M	320
	GGA GAA AAT GCG CCG TAC ATG ACA TTG CTA GGT GAC AGT GAT CAG ATG	
	920 930 940 950 960	
321	S F A P A E Y A Q L Y S F A M G	336
	AGC TTT GCA CCG GCT GAG TAT GCA CAG CTT TAT TCT TTT GCC ATG GGC	
	970 980 990 1000	
337	M A S V L D K G T G K Y Q F A R	352
	ATG GCA TCA GTC TTA GAT AAA GGA ACT GGC AAA TAC CAA TTC GCC AGA	
	1010 1020 1030 1040 1050	
353	D F M S T S F W R L G V E Y A Q	368
	GAC TTC ATG AGC ACA TCA TTC TGG AGA CTC GGG GTG GAG TAT GCT CAG	
	1060 1070 1080 1090 1100	
369	A Q G S S I N E D M A A E L K L	384
	GCT CAG GGG AGT AGC ATC AAC GAA GAC ATG GCT GCT GAG CTA AAA CTA	
	1110 1120 1130 1140 1150	

385 T P A A R R G L A A A A Q R V S 400
 ACC CCG GCA GCA AGA AGG GGC CTG GCA GCT GCT GCC CAA CGA GTG TCT
 1160 1170 1180 1190 1200
 5 401 E E T G S V D I P T Q Q A G V L 416
 GAG GAA ACT GGC AGC GTG GAT ATT CCT ACT CAA CAA GCC GGG GTC CTC
 1210 1220 1230 1240
 10 417 T G L S D G G P R A S Q G G S N 432
 ACT GGG CTC AGC GAT GGA GGC CCC CGA GCC TCT CAG GGT GGA TCG AAC
 1250 1260 1270 1280 1290
 433 K S Q G Q P D A G D G E T Q F L 448
 AAG TCG CAA GGG CAA CCA GAT GCC GGA GAT GGG GAG ACC CAA TTC TTG
 1300 1310 1320 1330 1340
 15 449 D L M R A V A N S M R E A P N S 464
 GAT TTG ATG AGA GCA GTG GCG AAC AGC ATG CGA GAA GCG CCA AAC TCC
 1350 1360 1370 1380 1390
 465 A Q S T T H P E P P P T P G P S 480
 GCA CAG AGC ACC ACC CAC CCG GAA CCC CCC CCG ACT CCC GGG CCA TCC
 1400 1410 1420 1430 1440
 20 481 Q D N D T D W G Y * 490
 CAA GAT AAC GAC ACC GAC TGG GGG TAT TGA
 1450 1460 1470

P gene: amino acid sequence

25 1 M A T F T D A E I D D I F E T S 16
 ATG GCC ACC TTT ACA GAT GCG GAG ATA GAT GAT ATA TTT GAG ACC AGT
 1 10 20 30 40
 30 17 G T V I D S I I T A Q G K S A E 32
 GGA ACT GTC ATT GAC AGC ATA ATT ACG GCC CAG GGT AAA TCA GCA GAG
 50 60 70 80 90
 33 T V G R S A I P Q G K T K A L S 48
 ACT GTC GGA AGG AGC GCA ATC CCA CAA GGC AAG ACC AAA GCG CTG AGC
 100 110 120 130 140

	49	I	A	W	E	K	H	G	S	I	Q	P	S	T	S	Q	D	64
		ATA	GCA	TGG	GAG	AAG	CAT	GGG	AGC	ATC	CAA	CCA	TCC	ACC	AGC	CAG	GAC	
		150				160				170				180			190	
5	65	N	P	D	Q	Q	D	R	P	D	K	Q	L	S	T	P	E	80
		AAC	CCC	GAC	CAA	CAG	GAT	AGA	CCA	GAC	AAA	CAG	CTA	TCC	ACA	CCT	GAG	
		200				210				220				230			240	
	81	Q	A	T	P	H	N	S	S	P	A	T	S	A	E	P	L	96
		CAG	GCG	ACC	CCA	CAC	AAC	AGC	TCG	CCA	GCC	ACA	TCC	GCC	GAA	CCG	CTC	
		250				260				270				280				
10	97	P	T	Q	A	A	G	E	A	G	D	T	Q	L	K	T	G	112
		CCC	ACT	CAG	GCC	GCA	GGT	GAG	GCC	GGC	GAC	ACA	CAG	CTC	AAG	ACC	GGA	
		290			300			310			320			330				
	113	A	S	N	S	L	L	S	M	L	D	K	L	S	N	K	P	128
		GCA	AGC	AAC	TCT	CTT	CTG	TCT	ATG	CTC	GAC	AAG	CTG	AGC	AAT	AAA	CCA	
15		340			350			360			370			380				
	129	S	N	A	K	K	G	P	W	S	S	P	Q	E	G	Y	H	144
		TCT	AAT	GCT	AAA	AAG	GGC	CCA	TGG	TCG	AGT	CCC	CAG	GAA	GGA	TAT	CAT	
		390			400			410			420			430				
	145	Q	P	P	T	Q	Q	H	G	D	Q	P	N	R	G	N	S	160
20		CAA	CCT	CCG	ACC	CAA	CAA	CAT	GGG	GAT	CAG	CCG	AAC	CGC	GGA	AAC	AGC	
		440			450			460			470			480				
	161	Q	E	R	L	R	H	Q	A	K	A	A	P	G	S	R	G	176
		CAG	GAG	AGG	CTG	CGG	CAC	CAA	GCC	AAG	GCC	GCC	CCT	GGA	AGC	CGG	GGC	
		490			500			510			520							
25	177	T	D	A	S	T	A	Y	H	G	Q	W	K	E	S	Q	L	192
		ACA	GAC	GCG	AGC	ACA	GCA	TAT	CAT	GGA	CAA	TGG	AAG	GAG	TCA	CAA	CTA	
		530			540			550			560			570				
	193	S	A	G	A	T	P	H	V	L	Q	S	G	Q	S	Q	D	208
		TCA	GCT	GGT	GCA	ACC	CCT	CAT	GTG	CTC	CAA	TCA	GGG	CAG	AGC	CAA	GAC	
30		580			590			600			610			620				
	209	S	T	P	V	P	V	D	H	V	Q	P	P	V	D	F	V	224
		AGT	ACT	CCT	GTA	CCT	GTG	GAT	CAT	GTC	CAG	CCA	CCT	GTC	GAC	TTT	GTG	
		630			640			650			660			670				

225 Q A M M T M M E A L S Q K V S K 240
 CAG GCG ATG ATG ACT ATG ATG GAG GCG TTA TCA CAG AAG GTA AGT AAA
 680 690 700 710 720
 241 V D Y Q L D L V L K Q T S S I P 256
 GTC GAC TAT CAG CTA GAC CTA GTC TTA AAG CAG ACA TCC TCC ATC CCT
 730 740 750 760
 257 M M R S E I Q Q L K T S V A V M 272
 ATG ATG CGG TCT GAA ATC CAA CAG CTA AAA ACA TCT GTT GCG GTC ATG
 770 780 790 800 810
 10 273 E A N L G M M K I L D P G C A N 288
 GAA GCT AAT TTA GGC ATG ATG AAA ATT CTG GAC CCT GGT TGT GCT AAC
 820 830 840 850 860
 289 I S S L S D L R A V A R S H P V 304
 ATT TCA TCC TTA AGT GAT CTG CGG GCA GTC GCC CGG TCC CAC CCA GTT
 15 870 880 890 900 910
 305 L I S G P G D P S P Y V T Q G G 320
 TTA ATT TCA GGC CCC GGA GAT CCG TCC CCC TAC GTG ACA CAA GGG GGT
 920 930 940 950 960
 20 321 E M T L N K L S Q P V Q H P S E 336
 GAG ATG ACA CTC AAT AAA CTC TCA CAA CCA GTA CAA CAC CCT TCC GAG
 970 980 990 1000
 337 L I K S A T A G G P D M G V E K 352
 TTA ATT AAA TCT GCC ACA GCG GGC GGA CCT GAT ATG GGA GTG GAA AAG
 1010 1020 1030 1040 1050
 25 353 D T V R A L I T S R P M H P S S 368
 GAC ACT GTC CGT GCA TTG ATC ACC TCG CGC CCG ATG CAT CCA AGC TCC
 1060 1070 1080 1090 1100
 369 S A K L L S K L D A A G S I E E 384
 TCA GCT AAG CTC CTG AGT AAG CTG GAT GCA GCC GGG TCG ATT GAA GAG
 30 1110 1120 1130 1140 1150
 385 I R K I K R L A L N G * 396
 ATC AGA AAG ATC AAG CGC CTT GCA CTA AAT GGC TAA
 1160 1170 1180

A primary use of the nucleotides as defined above is for the creation of plasmids using recombinant DNA technologies. The resulting recombinant molecule can then be introduced into an appropriate host. The plasmids thus created can be used to encode NP and P proteins. For expression of the NP and P proteins, any of the common expression
5 vectors, especially the bacterial vectors can be used. The usable bacterial hosts for the vectors include any of the conventional prokaryotic cells. In this invention, the bacterial host used was *Escherichia coli*. Accordingly, a further aspect of the present invention provides for a prokaryotic cell, such as for example a bacterial cell and in particular an *E. coli* cell containing the nucleotides as defined above for the production of NP and P
10 proteins.

The NP and P proteins, produced using recombinant plasmids in accordance with the present invention, can be in the fusion or non-fusion forms. In accordance with the embodiment of the present invention, it provides a method for producing the fusion and non-fusion forms of both the NP and P proteins of NDV virus strain AF2240 in an *E. coli*
15 system. The preferred method for producing the fusion and non-fusion forms of both the NP and P proteins of NDV virus strain AF2240 comprises culturing the transformed *E. coli* of the present invention on an appropriate medium to express the said nucleocapsid protein and phosphoprotein, and isolating and purifying the expressed fusion proteins from the cultures.

20 While the invention will now be described in connection with certain preferred embodiments in the following experiments so that aspects thereof may be more fully understood and appreciated, it is not intended to limit the invention to these particular embodiments. On the contrary, it is intended to cover all alternatives, modifications and equivalents as may be included within the scope of the invention as defined by the
25 appended claims.

Brief description of the figures

Figure 1 is a western blot of NDV nucleocapsid protein (NP) expressed by transformed *E. coli* TOP10 containing plasmid pTrcHis2-NP

Figure 2 is a western blot of NDV phosphoprotein (P) expressed by transformed *E. coli*
30 TOP10 containing plasmid pTrcHis2-P

Detailed description of the invention

The present invention was accomplished through the employment of the recombinant DNA techniques which comprises the amplification of the NP and P coding regions of NDV strain AF2240, the cloning of the genes into the expression vector, the production of the transformed *E. coli*, the cultivation of the transformant, the expression of the NP and P proteins and the purification of the expressed fusion proteins.

The NP and P coding regions of NDV strain AF2240 which had been cloned into the expression vector were prepared through reverse transcription-polymerase chain reaction (RT-PCR). Three primers were used for each gene, which consisted of one forward and two reverse primers as listed below:

For the amplification of the NP gene

NPf1 (20 mer): 5'- cct tct gcc aac atg tct tc -3' (Forward primer)

NPr1 (20 mer): 5'- tca ata ccc cca gtc ggt gt -3' (Reverse primer)

NPr2 (18 mer): 5'- ata ccc cca gtc ggt gtc -3' (Reverse primer)

For the amplification of the P gene

Pf1 (20 mer): 5'- atg gcc acc ttt aca gat gc -3' (Forward primer)

Pr1 (23 mer): 5'- taa tta gcc att tag tgc aag gc -3' (Reverse primer)

Pr2 (21 mer): 5'- gcc att tag tgc aag gcg ctt -3' (Reverse primer)

Incorporation of primers designated as NPf1 and NPr1 (for the NP gene), or Pf1 and Pr1 (for the P gene) during PCR had amplified gene products containing a stop codon at their 3' ends, while the presence of primers NPf1 and NPr2 (for the NP gene) or Pf1 and Pr2 (for the P gene) gave rise to genes without any no stop codon. For cloning and expression purposes, a commercially available expression vector, pTrcHis2 (Invitrogen, USA) containing the coding regions for the *myc* epitope and 6 His residues downstream of the multiple cloning site was used. After cloning of the respective coding regions of NP and P genes into the pTrcHis2 vector, they were subsequently introduced into a bacterial host *E. coli* TOP10. The resulting plasmid harbouring the NP gene was designated as pTrcHis2-NP while the other one with the P gene as an insert was denoted as pTrcHis2-P. Both the

NP and P proteins were expressed in *E.coli* TOP10 cells as non-fusion and fusion proteins. The latter forms contain the *myc* epitope and 6 His residues at their C termini. For protein identification, protein samples were analysed with SDS- PAGE and then followed by immunoblotting with the anti-NDV chicken serum and the anti-*myc* monoclonal antibody. The western blots for NP and P proteins are as shown in Figure 1 and Figure 2, respectively.

The expressed NP fusion protein was purified with affinity chromatography (nickel column), and was judged to be more than 90% pure by SDS-PAGE.

The nucleotide sequences of the NP and P genes were determined by the ABI PRISM automated sequencer, model 377. The recombinant plasmids, pTrcHis2-NP and pTrcHis2-P, were used as templates and the synthetic primers used in the sequencing reactions of the NP and P genes are as follows:

For the sequencing of the NP gene coding region

pTrcHis2F (21 mer): 5'- gag gta tat att aat gta tcg -3'
 15 sNPf1 (21 mer): 5'- gac tca tac atc agg aac acc -3'
 sNPf2 (21 mer): 5'- gat gag agc agt ggc gaa cag -3'
 pTrcHis2R (18 mer): 5'- gat tta atc tgt atc agg -3'
 sNPr1 (20 mer): 5'- tca ata ccc cca gtc ggt gt -3'
 sNPr2 (21 mer): 5'- cta agt tgt aat acg tgg agc -3'
 20 sNPr3 (21 mer): 5'- cca tcg atc tca aga aca tgc -3'

For the sequencing of the P gene coding region

pTrcHis2F (21 mer): 5'- gag gta tat att aat gta tcg -3'
 sPf1 (21 mer): 5'- gtc gac ttt gtg cag gcg atg -3'
 sPf2 (21 mer): 5'- gga cac tgt ccg tgc att gat -3'
 25 pTrcHis2.R (18 mer): 5'- gat tta atc tgt atc agg -3'
 sPr1 (21 mer): 5'- cca ggg tcc aga att ttc atc -3'
 sPr2 (22 mer): 5'- ggt gtg gat agc tgt ttg tct g -3'

Both the NP and P coding regions were sequenced from 5' to 3' direction and reversely from 3' to 5' direction.

5 Example I illustrates the recombinant DNA techniques employed in obtaining bacterial clones harbouring a plasmid containing inserts of NP and P coding cDNA for NDV genomic RNA, the nucleotide sequences of the NP and P genes, and also the expressed NP and P proteins.

EXAMPLE I

Virus Propagation

10 The stock of NDV strain AF2240 was originally obtained from the Veterinary Research Institute (VRI), Ipoh. The virus was grown in the allantoic cavity of 8 to 9 day-old chicken embryonated eggs according to the procedures of Blaskovic and Styk (1967). After 3 - 4 days of incubation at 37°C, the eggs were chilled overnight at 4°C. The allantoic fluid was then harvested and the presence of the viruses was determined by haemagglutination (HA) test. The allantoic fluid which showed positive reaction of HA
15 test was then clarified by centrifugation at 6000 xg for 20 min at 4°C (Beckman, JA14 rotor, USA) to remove debris.

Genomic RNA extraction

20 Total RNA was extracted using the Trizol LS reagent (Gibco BRL, USA). Briefly, 250 µl of the virus infected allantoic fluid was mixed with 750 µl Trizol LS reagent and incubated for 5 min at room temperature. After incubation, 100 µl of 1-bromo-3-chloropropane (BCP) (MRC, UK) was added and the mixtures were mixed vigorously for about 15 s and again incubated at room temperature for 10 min. The mixtures were phase separated by microcentrifuging at 13,000 xg for 15 min at 4°C (Jouan MR 1812, France). The RNA was then precipitated by adding 500 µl of isopropanol (Merck) to the
25 aqueous phase and left at room temperature for 10 min. The precipitated RNA was microcentrifuged at 13,000 xg for 10 min and the pellet obtained was washed once with 75% (v/v) diethyl pyrocarbonate (DEPC) (Sigma, USA) treated ethanol (Hamburg). The pellet was dissolved in 20 µl of DEPC treated dH₂O.

cDNA synthesis and amplification of nucleocapsid (NP) and phosphoprotein (P) genes by RT-PCR

The amplification reactions were carried out in a programmed thermal cycler (MJ Research Inc. USA). Synthesis of the first strand cDNA was performed in a final volume of 30 μ l. The reaction mixture contained 0.4 μ M of each the forward and reverse primers, 0.2 mM deoxynucleoside triphosphate (MBI Fermentas, Inc. USA), 5 U of AMV reverse transcriptase (Promega, USA), 8 U of RNase inhibitor (Gibco BRL, USA), 1.5 mM of $MgCl_2$ and 1x of reaction buffer (50 mM Tris-HCl, 15 mM $(NH_4)_2SO_4$, 0.1% Triton X-100). The mixture was incubated at 42°C for 30 min to synthesise the first strand of cDNA, and then 94°C for 3 min to inactivate the reverse transcriptase.

For the amplification of the respective NP and P genes, another 20 μ l of reaction mixture containing 1 U of DyNAzyme EXT DNA polymerase (FINNZYMES), 1.5 mM of $MgCl_2$ and 1 x of reaction buffer was added to the top of the above cDNA mixture which was held at 94°C in the thermal cycler. The PCR profile for the amplification of NP gene comprising denaturation at 94°C for 30 s, annealing at 55°C for 50 s and extension at 72°C for 1 min for a total of 30 cycles. To ensure a complete synthesis of the PCR product, the extension step at 72°C was prolonged for 7 min after the last cycle. The PCR profile for the amplification of P gene was basically similar to that of NP gene, except the annealing step was carried out at 55°C for 30 s.

Purification of the amplified PCR products

A total of 40 μ l of the amplified PCR product was analysed on 1% TAE agarose gel. After the staining with ethidium bromide, the band with the correct size was excised from the gel and purified with the Wizard PCR Preps DNA Purification System (Promega, USA) according to the manufacturer's procedures. After purification, 5 μ l of the PCR product was again analysed with agarose gel electrophoresis to determine the recovery of the PCR product, which would be used in TA cloning.

TOPO TA Cloning of NP and P genes

Four μ l of the purified NP or P DNA fragments carrying an A overhang at their 3' ends was mixed with 1 μ l of the pTrcHis2 TOPO expression vector (Invitrogen, USA) and the ligation reaction was carried out at room temperature (25°C) for 5 min to form the desired recombinant plasmid.

Transformation

For transformation, 5 μ l of the ligation mixture was added to 50 μ l of TOP10 *E. coli* competent cells (Invitrogen, USA). The transformation mixture was incubated on ice for 30 min and the cells were heated at 42°C for 30 to 60 s. This was followed by the adding of 250 μ l SOC medium (2% trypton, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄, 20 mM glucose) and the incubation of the reaction mixture at 37°C for 30 to 60 min with shaking at 250 rpm. Thirty-50 μ l of the transformation mixture was spread on a LB plate containing 50 μ g/ml ampicillin and 0.5% of glucose, and the plates were then incubated overnight at 37°C.

Screening for positive clones

Ten single colonies were randomly chosen and cultured overnight in 3 to 5 ml of LB medium containing 50 μ g/ml ampicillin and 0.5% glucose. Plasmid DNA was isolated by using the alkaline lysis method and the orientation of the insert in the positive clones was confirmed by PCR.

Protein expression

The identified positive clones were cultured overnight in LB medium containing 50 μ g/ml ampicillin. The next day, 10 ml of LB medium containing 50 μ g/ml ampicillin was inoculated with 0.2 ml of the overnight culture and incubated at 37°C with shaking at 250 rpm. Once the cells reached the optical density of 0.6 to 0.8 at A₆₀₀, 1 mM IPTG was

added into the culture and continued shaking for 3 to 5 hours. The cells were harvested from the culture by centrifugation and then subjected to polyacrylamide gel electrophoresis (SDS-PAGE).

SDS-PAGE and western blotting

5 The cell pellets (from 1 ml culture solution) were resuspended in 50 to 100 μ l of 1X SDS-PAGE sample buffer and boiled for 10 min. Five to 10 μ l of the sample was loaded onto 12% SDS-PAGE gel and electrophoresed for 70 to 80 min at 32 volt. The proteins on SDS-PAGE gel were then electro-transferred onto a nitrocellulose membrane for 1 h. Western blotting was carried out by blocking the membrane first with skim milk for 1 h to
10 saturate unoccupied regions on the membrane. This was followed by adding the anti-NDV chicken serum or anti-*myc* monoclonal antibody (for fusion protein) onto the membrane and this was shaken for 1 h at room temperature. The membrane was then washed four times with TTBS washing solution (TBS containing 0.5% Tween 20), 5 to 10 min for each wash to remove the unbound antibodies. After washing, peroxidase-
15 labelled antibody was added to react with the primary antibody and left shaking for another 1 h. The membrane was further washed four times with TTBS solution, each for 5 to 10 min, and lastly BCIP/NBT solution was added as substrate for the peroxidase. The molecular weight of NP and P proteins was about 55 kDa while the fusion form for both the NP and P proteins gave rise to an apparent molecular weight of about 60 kDa.

20 Purification of NP fusion protein using ProBond Column

Two hundred μ l of LB medium containing 50 μ g/ml ampicillin was cultured with 2 ml of overnight culture of transformant harbouring plasmid pTrcHis2-NP (carrying the NP insert without a stop codon), and the cells were grown to an OD₆₀₀ of 0.6 to 0.8. Protein expression was then induced by adding 1 mM IPTG and the cells were grown for another
25 5 h. The cells were harvested by centrifugation at 2000 xg for 15 min at 4°C. The cell pellet was first resuspended in 10 ml of binding buffer (500 mM NaCl, 20 mM NaH₂PO₄, pH 7.8), then 100 μ g/ml of lysozyme was added and incubated for 15 min on ice. The cells were lysed by sonication until the cell lysate is no longer viscous. The cell lysate was then treated with RNase and DNase I, both at a concentration of 5 μ g/ml for 15 min at
30 30°C. The cell lysate was then centrifuged at 10,000 xg for 20 min to remove all the cell

debris. The supernatant was collected and passed through a 0.45 µm filter. This cell lysate was incubated with the ProBond resin (Invitrogen, USA) for 30 min and then allowed to drip through the resin. The column was washed with 10 ml of washing buffer (50 mM Imidazole, 500 mM NaCl, 20 mM NaH₂PO₄, pH 6.0), and the proteins were then eluted with 5 ml of elution buffer (500 mM Imidazole, 500 mM NaCl, 20 mM NaH₂PO₄, pH 6.0). The elute was collected as 1 ml fractions. Samples from each fractions were analysed on 12% SDS-PAGE to check the purity of the protein.

REFERENCES

Abdul Rahman, M.S., Chee, Y.S. and Lim, S.S. (1976) Observation on the response of breeder flocks to ranikhet standard vaccination. *Kajian Vet.* **8**: 48 – 53.

Blaskovic, D. and Styk, B. (1967) Laboratory methods of virus transmission in multicellular organisms. *In*: Maramorasch, K. and Koprovski, H. (Eds.), *Virology*, Vol. 1. Academic Press, New York, pp. 194 – 197.

Idris, Z., Yusoff, K., Shamaan, N.A. and Ibrahim, A.L. (1993) The Effect of temperature on different strains of Newcastle disease virus. 2nd. UNESCO National Workshop on Promotion of Microbiology in Malaysia, 38.

Jemain, S.F.P. (1999) Sequence determination of the Matrix gene in Newcastle disease virus strain AF2240. MS thesis, Universiti Putra Malaysia.

Lai, C.M. (1985) A Study on a velogenic viscerotropic Newcastle disease virus *in-vitro* and *in-vivo*. PhD thesis, Universiti Pertanian Malaysia.

Salih, O., Omar, A.R., Ali, A.M. and Yusoff, K. (2000) Nucleotide sequence analysis of the F protein gene of a Malaysian velogenic NDV strain AF2240. *Journal of Biochemistry, Molecular Biology and Biophysics* **4**: 51-57.

Tan, W.S., Lau, C.H., Ng, B.K., Ibrahim, A.L. and Yusoff, K. (1995) Nucleotide sequence of the haemagglutinin-neuraminidase (HN) gene of a Malaysian heat resistant viscerotropic-velogenic Newcastle disease virus (NDV) strain AF2240. DNA Sequence 6: 47-50.

CLAIMS

1. Nucleotides encoding the full length or part of the nucleocapsid (NP) protein of Newcastle disease virus (NDV).

2. The nucleotides as claimed in claim 1 characterised in that it has the following nucleotide sequence:

5

10

15

20

25

30

	10	20	30	40	50	60
	ATGTCTTCCG	TATTCGATGA	ATACGAGCAG	CTCCTCGCTG	CTCAGACTCG	CCCCAATGGA
	70	80	90	100	110	120
	GCTCACGGAG	GGGGAGAGAG	AGGGAGCACT	TTAAGAGTTG	AGGTCCCAGT	ATTCACTCTT
10	130	140	150	160	170	180
	AACAGTGACG	ATCCAGAAGA	TAGATGGAAT	TTTGCGGTAT	TCTGTCTTCG	GATTGCTGTT
	190	200	210	220	230	240
	AGCGAGGACG	CCAACAAACC	GCTCAGGCAA	GGTGCTCTCA	TATCCCTCCT	GTGCTCCCAT
15	250	260	270	280	290	300
	TCTCAAGTGA	TGAGGAACCA	TGTTGCCCTT	GCAGGAAAAC	AGAATGAGGC	TACTACTGACT
	310	320	330	340	350	360
	GTTCTTGAGA	TCGATGGTTT	TACCAGCAGC	GTGCCTCAGT	TCAACAACAG	GAGTGGGGTG
	370	380	390	400	410	420
	TCTGAGGAGA	GAGCACAGAG	ATTCATGGTG	ATAGCAGGGT	CTCTCCCTCG	GGCGTGCAGT
20	430	440	450	460	470	480
	AACGGTACTC	CGTTCGTCAC	GGCTGGGGTT	GAAGATGATG	CACCAGAAGA	TATCACTGAT
	490	500	510	520	530	540
	ACTCTGGAAA	GAATCCTGTC	TATCCAGGCT	CAGGTATGGG	TCACAGTAGC	GAAGGCCATG
25	550	560	570	580	590	600
	ACTGCATATG	AGACAGCAGA	TGAGTCGGAA	ACAAGAAGAA	TCAATAAGTA	CATGCAGCAA
	610	620	630	640	650	660
	GGCAGAGTCC	AGAAGAAGTA	CATCCTCCAC	CCTGTATGCA	GGAGTGCAAT	TCAACTCACA
	670	680	690	700	710	720
	ATCAGACATT	CTCTGGCAGT	CCGCATTTTC	TTAGTTAGCG	AGCTTAAGAG	AGGCCGCAAT
30	730	740	750	760	770	780
	ACGGCAGGTG	GGAGCTCCAC	GTATTACAAC	TTAGTAGGGG	ATGTAGACTC	ATACATCAGG
	790	800	810	820	830	840
	AACACCGGAC	TTACTGCATT	CTTCCTTACA	CTCAAATATG	GAATTAATAC	CAAGACATCA

	850	860	870	880	890	900
	GCCCTAGCAC	TCAGCAGCCT	CACAGGCGAT	ATCCAAAAGA	TGAAGCAGCT	CATGCGTTTA
	910	920	930	940	950	960
	TATCGGATGA	AGGGAGAAAA	TGCGCCGTAC	ATGACATTGC	TAGGTGACAG	TGATCAGATG
5	970	980	990	1000	1010	1020
	AGCTTTGCAC	CGGCTGAGTA	TGCACAGCTT	TATTCTTTTG	CCATGGGCAT	GGCATCAGTC
	1030	1040	1050	1060	1070	1080
	TTAGATAAAG	GAAGTGGCAA	ATACCAATTC	GCCAGAGACT	TCATGAGCAC	ATCATTCTGG
10	1090	1100	1110	1120	1130	1140
	AGACTCGGGG	TGGAGTATGC	TCAGGCTCAG	GGGAGTAGCA	TCAACGAAGA	CATGGCTGCT
	1150	1160	1170	1180	1190	1200
	GAGCTAAAAC	TAACCCCGGC	AGCAAGAAGG	GGCCTGGCAG	CTGCTGCCCCA	ACGAGTGTCT
	1210	1220	1230	1240	1250	1260
	GAGGAAACTG	GCAGCGTGGA	TATTCCTACT	CAACAAGCCG	GGGTCCTCAC	TGGGCTCAGC
15	1270	1280	1290	1300	1310	1320
	GATGGAGGCC	CCCAGGCCTC	TCAGGGTGGA	TCGAACAAGT	CGCAAGGGCA	ACCAGATGCC
	1330	1340	1350	1360	1370	1380
	GGAGATGGGG	AGACCCAATT	CTTGGATTG	ATGAGAGCAG	TGGCGAACAG	CATGCGAGAA
20	1390	1400	1410	1420	1430	1440
	GCGCCAAACT	CCGCACAGAG	CACCACCCAC	CCGGAACCCC	CCCCGACTCC	CGGGCCATCA
	1450	1460	1470	1480	1490	1500
	CAAGATAACG	ACACCGACTG	GGGGTATTGA

3. Nucleotides encoding the full length or part of the phosphoprotein (P) of Newcastle disease virus (NDV).

25 4. The nucleotides as claimed in claim 3 characterised in that it has the following nucleotide sequence:

	10	20	30	40	50	60
	ATGGCCACCT	TTACAGATGC	GGAGATAGAT	GATATATTTG	AGACCAGTGG	AACTGTCATT
30	70	80	90	100	110	120
	GACAGCATAA	TTACGGCCCCA	GGGTAAATCA	GCAGAGACTG	TCGGAAGGAG	CGCAATCCCA
	130	140	150	160	170	180
	CAAGGCAAGA	CCAAAGCGCT	GAGCATAGCA	TGGGAGAAGC	ATGGGAGCAT	CCAACCATCC
	190	200	210	220	230	240
	ACCAGCCAGG	ACAACCCCGA	CCAACAGGAT	AGACCAGACA	AACAGCTATC	CACACCTGAG
35	250	260	270	280	290	300
	CAGGCGACCC	CACACAACAG	CTCGCCAGCC	ACATCCGCCG	AACCGCTCCC	CACTCAGGCC

310 320 330 340 350 360
 GCAGGTGAGG CCGGCGACAC ACAGCTCAAG ACCGGAGCAA GCAACTCTCT TCTGTCTATG
 370 380 390 400 410 420
 CTCGACAAGC TGAGCAATAA ACCATCTAAT GCTAAAAAGG GCCCATGGTC GAGTCCCCAG
 5 430 440 450 460 470 480
 GAAGGATATC ATCAACCTCC GACCCAACAA CATGGGGATC AGCCGAACCG CGGAAACAGC
 490 500 510 520 530 540
 CAGGAGAGGC TGCGGCACCA AGCCAAGGCC GCCCCTGGAA GCCGGGGCAC AGACGCGAGC
 550 560 570 580 590 600
 10 ACAGCATATC ATGGACAATG GAAGGAGTCA CAACTATCAG CTGGTGCAAC CCCTCATGTG
 610 620 630 640 650 660
 CTCCAATCAG GGCAGAGCCA AGACAGTACT CCTGTACCTG TGGATCATGT CCAGCCACCT
 670 680 690 700 710 720
 GTCGACTTTG TGCAGGCGAT GATGACTATG ATGGAGGCGT TATCACAGAA GGTAAGTAAA
 15 730 740 750 760 770 780
 GTCGACTATC AGCTAGACCT AGTCTTAAAG CAGACATCCT CCATCCCTAT GATGCGGTCT
 790 800 810 820 830 840
 GAAATCCAAC AGCTAAAAAC ATCTGTTGCG GTCATGGAAG CTAATTTAGG CATGATGAAA
 850 860 870 880 890 900
 20 ATTCTGGACC CTGGTTGTGC TAACATTTCA TCCTTAAGTG ATCTGCGGGC AGTCGCCCGG
 910 920 930 940 950 960
 TCCCACCCAG TTTTAATTTT AGGCCCCGGA GATCCGTCCC CCTACGTGAC ACAAGGGGGT
 970 980 990 1000 1010 1020
 GAGATGACAC TCAATAAACT CTCACAACCA GTACAACACC CTTCCGAGTT AATTAAATCT
 25 1030 1040 1050 1060 1070 1080
 GCCACAGCGG GCGGACCTGA TATGGGAGTG GAAAAGGACA CTGTCCGTGC ATTGATCACC
 1090 1100 1110 1120 1130 1140
 TCGCGCCCGA TGCATCCAAG CTCCTCAGCT AAGCTCCTGA GTAAGCTGGA TGCAGCCGGG
 1150 1160 1170 1180 1190 1200
 30 TCGATTGAAG AGATCAGAAA GATCAAGCGC CTTGCACTAA ATGGCTAA..

5. The NP protein coded according to claim 1 or claim 2 characterised in that it has the following amino acid sequence:

1 M S S V F D E Y E Q L L A A Q T 16
 ATG TCT TCC GTA TTC GAT GAA TAC GAG CAG CTC CTC GCT GCT CAG ACT
 1 10 20 30 40
 17 R P N G A H G G G E R G S T L R 32
 CGC CCC AAT GGA GCT CAC GGA GGG GGA GAG AGA GGG AGC ACT TTA AGA
 50 60 70 80 90

	33	V	E	V	P	V	F	T	L	N	S	D	D	P	E	D	R	48
		GTT	GAG	GTC	CCA	GTA	TTC	ACT	CTT	AAC	AGT	GAC	GAT	CCA	GAA	GAT	AGA	
		100			110				120			130			140			
5	49	W	N	F	A	V	F	C	L	R	I	A	V	S	E	D	A	64
		TGG	AAT	TTT	GCG	GTA	TTC	TGT	CTT	CGG	ATT	GCT	GTT	AGC	GAG	GAC	GCC	
		150			160				170			180			190			
	65	N	K	P	L	R	Q	G	A	L	I	S	L	L	C	S	H	80
		AAC	AAA	CCG	CTC	AGG	CAA	GGT	GCT	CTC	ATA	TCC	CTC	CTG	TGC	TCC	CAT	
		200			210				220			230			240			
10	81	S	Q	V	M	R	N	H	V	A	L	A	G	K	Q	N	E	96
		TCT	CAA	GTG	ATG	AGG	AAC	CAT	GTT	GCC	CTT	GCA	GGA	AAA	CAG	AAT	GAG	
		250			260				270			280						
15	97	A	T	L	T	V	L	E	I	D	G	F	T	S	S	V	P	112
		GCT	ACA	CTG	ACT	GTT	CTT	GAG	ATC	GAT	GGT	TTT	ACC	AGC	AGC	GTG	CCT	
		290			300				310			320			330			
	113	Q	F	N	N	R	S	G	V	S	E	E	R	A	Q	R	F	128
		CAG	TTC	AAC	AAC	AGG	AGT	GGG	GTG	TCT	GAG	GAG	AGA	GCA	CAG	AGA	TTC	
		340			350				360			370			380			
20	129	M	V	I	A	G	S	L	P	R	A	C	S	N	G	T	P	144
		ATG	GTG	ATA	GCA	GGG	TCT	CTC	CCT	CGG	GCG	TGC	AGT	AAC	GGT	ACT	CCG	
		390			400				410			420			430			
	145	F	V	T	A	G	V	E	D	D	A	P	E	D	I	T	D	160
		TTC	GTC	ACG	GCT	GGG	GTT	GAA	GAT	GAT	GCA	CCA	GAA	GAT	ATC	ACT	GAT	
		440			450				460			470			480			
25	161	T	L	E	R	I	L	S	I	Q	A	Q	V	W	V	T	V	176
		ACT	CTG	GAA	AGA	ATC	CTG	TCT	ATC	CAG	GCT	CAG	GTA	TGG	GTC	ACA	GTA	
		490			500				510			520						
30	177	A	K	A	M	T	A	Y	E	T	A	D	E	S	E	T	R	192
		GCG	AAG	GCC	ATG	ACT	GCA	TAT	GAG	ACA	GCA	GAT	GAG	TCG	GAA	ACA	AGA	
		530			540				550			560			570			
	193	R	I	N	K	Y	M	Q	Q	G	R	V	Q	K	K	Y	I	208
		AGA	ATC	AAT	AAG	TAC	ATG	CAG	CAA	GGC	AGA	GTC	CAG	AAG	AAG	TAC	ATC	
		580			590				600			610			620			
35	209	L	H	P	V	C	R	S	A	I	Q	L	T	I	R	H	S	224
		CTC	CAC	CCT	GTA	TGC	AGG	AGT	GCA	ATT	CAA	CTC	ACA	ATC	AGA	CAT	TCT	
		630			640				650			660			670			
	225	L	A	V	R	I	F	L	V	S	E	L	K	R	G	R	N	240
		CTG	GCA	GTC	CGC	ATT	TTC	TTA	GTT	AGC	GAG	CTT	AAG	AGA	GGC	CGC	AAT	
		680			690				700			710			720			
40	241	T	A	G	G	S	S	T	Y	Y	N	L	V	G	D	V	D	256
		ACG	GCA	GGT	GGG	AGC	TCC	ACG	TAT	TAC	AAC	TTA	GTA	GGG	GAT	GTA	GAC	
		730			740				750			760						
45	257	S	Y	I	R	N	T	G	L	T	A	F	F	L	T	L	K	272
		TCA	TAC	ATC	AGG	AAC	ACC	GGA	CTT	ACT	GCA	TTC	TTC	CTT	ACA	CTC	AAA	
		770			780				790			800			810			
	273	Y	G	I	N	T	K	T	S	A	L	A	L	S	S	L	T	288
		TAT	GGA	ATT	AAT	ACC	AAG	ACA	TCA	GCC	CTA	GCA	CTC	AGC	AGC	CTC	ACA	
		820			830				840			850			860			
50	289	G	D	I	Q	K	M	K	Q	L	M	R	L	Y	R	M	K	304
		GGC	GAT	ATC	CAA	AAG	ATG	AAG	CAG	CTC	ATG	CGT	TTA	TAT	CGG	ATG	AAG	
		870			880				890			900			910			

305	G	E	N	A	P	Y	M	T	L	L	G	D	S	D	Q	M	320
	GGA	GAA	AAT	GCG	CCG	TAC	ATG	ACA	TTG	CTA	GGT	GAC	AGT	GAT	CAG	ATG	
		920				930			940			950				960	
321	S	F	A	P	A	E	Y	A	Q	L	Y	S	F	A	M	G	336
5	AGC	TTT	GCA	CCG	GCT	GAG	TAT	GCA	CAG	CTT	TAT	TCT	TTT	GCC	ATG	GGC	
		970				980			990				1000				
337	M	A	S	V	L	D	K	G	T	G	K	Y	Q	F	A	R	352
10	ATG	GCA	TCA	GTC	TTA	GAT	AAA	GGA	ACT	GGC	AAA	TAC	CAA	TTC	GCC	AGA	
	1010		1020			1030			1040			1050					
353	D	F	M	S	T	S	F	W	R	L	G	V	E	Y	A	Q	368
	GAC	TTC	ATG	AGC	ACA	TCA	TTC	TGG	AGA	CTC	GGG	GTG	GAG	TAT	GCT	CAG	
	1060		1070			1080			1090			1100					
369	A	Q	G	S	S	I	N	E	D	M	A	A	E	L	K	L	384
15	GCT	CAG	GGG	AGT	AGC	ATC	AAC	GAA	GAC	ATG	GCT	GCT	GAG	CTA	AAA	CTA	
	1110			1120			1130			1140			1150				
385	T	P	A	A	R	R	G	L	A	A	A	A	Q	R	V	S	400
	ACC	CCG	GCA	GCA	AGA	AGG	GGC	CTG	GCA	GCT	GCT	GCC	CAA	CGA	GTG	TCT	
	1160			1170			1180			1190			1200				
401	E	E	T	G	S	V	D	I	P	T	Q	Q	A	G	V	L	416
20	GAG	GAA	ACT	GGC	AGC	GTG	GAT	ATT	CCT	ACT	CAA	CAA	GCC	GGG	GTC	CTC	
	1210			1220			1230			1240							
417	T	G	L	S	D	G	G	P	R	A	S	Q	G	G	S	N	432
25	ACT	GGG	CTC	AGC	GAT	GGA	GGC	CCC	CGA	GCC	TCT	CAG	GGT	GGA	TCG	AAC	
	1250		1260			1270			1280			1290					
433	K	S	Q	G	Q	P	D	A	G	D	G	E	T	Q	F	L	448
	AAG	TCG	CAA	GGG	CAA	CCA	GAT	GCC	GGA	GAT	GGG	GAG	ACC	CAA	TTC	TTG	
	1300		1310			1320			1330			1340					
449	D	L	M	R	A	V	A	N	S	M	R	E	A	P	N	S	464
30	GAT	TTG	ATG	AGA	GCA	GTG	GCG	AAC	AGC	ATG	CGA	GAA	GCG	CCA	AAC	TCC	
	1350		1360			1370			1380			1390					
465	A	Q	S	T	T	H	P	E	P	P	P	T	P	G	P	S	480
	GCA	CAG	AGC	ACC	ACC	CAC	CCG	GAA	CCC	CCC	CCG	ACT	CCC	GGG	CCA	TCC	
	1400		1410			1420			1430			1440					
481	Q	D	N	D	T	D	W	G	Y	*							490
35	CAA	GAT	AAC	GAC	ACC	GAC	TGG	GGG	TAT	TGA							
	1450		1460			1470											

6. The P protein coded according to claim 3 or claim 4 characterised in that it has the following amino acid sequence:

40	1	M	A	T	F	T	D	A	E	I	D	D	I	F	E	T	S	16
		ATG	GCC	ACC	TTT	ACA	GAT	GCG	GAG	ATA	GAT	GAT	ATA	TTT	GAG	ACC	AGT	
		1		10		20		30		40								
45	17	G	T	V	I	D	S	I	I	T	A	Q	G	K	S	A	E	32
		GGA	ACT	GTC	ATT	GAC	AGC	ATA	ATT	ACG	GCC	CAG	GGT	AAA	TCA	GCA	GAG	
		50		60		70		80		90								

5	33	T	V	G	R	S	A	I	P	Q	G	K	T	K	A	L	S	48
		ACT	GTC	GGA	AGG	AGC	GCA	ATC	CCA	CAA	GGC	AAG	ACC	AAA	GCG	CTG	AGC	
		100			110				120			130			140			
	49	I	A	W	E	K	H	G	S	I	Q	P	S	T	S	Q	D	64
		ATA	GCA	TGG	GAG	AAG	CAT	GGG	AGC	ATC	CAA	CCA	TCC	ACC	AGC	CAG	GAC	
10		150			160				170			180			190			
	65	N	P	D	Q	Q	D	R	P	D	K	Q	L	S	T	P	E	80
		AAC	CCC	GAC	CAA	CAG	GAT	AGA	CCA	GAC	AAA	CAG	CTA	TCC	ACA	CCT	GAG	
		200			210				220			230			240			
	81	Q	A	T	P	H	N	S	S	P	A	T	S	A	E	P	L	96
15		CAG	GCG	ACC	CCA	CAC	AAC	AGC	TCG	CCA	GCC	ACA	TCC	GCC	GAA	CCG	CTC	
		250			260				270			280						
	97	P	T	Q	A	A	G	E	A	G	D	T	Q	L	K	T	G	112
		CCC	ACT	CAG	GCC	GCA	GGT	GAG	GCC	GGC	GAC	ACA	CAG	CTC	AAG	ACC	GGA	
		290			300			310			320			330				
20	113	A	S	N	S	L	L	S	M	L	D	K	L	S	N	K	P	128
		GCA	AGC	AAC	TCT	CTT	CTG	TCT	ATG	CTC	GAC	AAG	CTG	AGC	AAT	AAA	CCA	
		340			350			360			370			380				
	129	S	N	A	K	K	G	P	W	S	S	P	Q	E	G	Y	H	144
		TCT	AAT	GCT	AAA	AAG	GGC	CCA	TGG	TCG	AGT	CCC	CAG	GAA	GGA	TAT	CAT	
25		390			400			410			420			430				
	145	Q	P	P	T	Q	Q	H	G	D	Q	P	N	R	G	N	S	160
		CAA	CCT	CCG	ACC	CAA	CAA	CAT	GGG	GAT	CAG	CCG	AAC	CGC	GGA	AAC	AGC	
		440			450			460			470			480				
	161	Q	E	R	L	R	H	Q	A	K	A	A	P	G	S	R	G	176
30		CAG	GAG	AGG	CTG	CGG	CAC	CAA	GCC	AAG	GCC	GCC	CCT	GGA	AGC	CGG	GGC	
		490			500			510			520			530				
	177	T	D	A	S	T	A	Y	H	G	Q	W	K	E	S	Q	L	192
		ACA	GAC	GCG	AGC	ACA	GCA	TAT	CAT	GGA	CAA	TGG	AAG	GAG	TCA	CAA	CTA	
		540			550			560			570			580				
35	193	S	A	G	A	T	P	H	V	L	Q	S	G	Q	S	Q	D	208
		TCA	GCT	GGT	GCA	ACC	CCT	CAT	GTG	CTC	CAA	TCA	GGG	CAG	AGC	CAA	GAC	
		590			600			610			620			630				
	209	S	T	P	V	P	V	D	H	V	Q	P	P	V	D	F	V	224
		AGT	ACT	CCT	GTA	CCT	GTG	GAT	CAT	GTC	CAG	CCA	CCT	GTC	GAC	TTT	GTG	
40		640			650			660			670			680				
	225	Q	A	M	M	T	M	M	E	A	L	S	Q	K	V	S	K	240
		CAG	GCG	ATG	ATG	ACT	ATG	ATG	GAG	GCG	TTA	TCA	CAG	AAG	GTA	AGT	AAA	
		690			700			710			720			730				
	241	V	D	Y	Q	L	D	L	V	L	K	Q	T	S	S	I	P	256
45		GTC	GAC	TAT	CAG	CTA	GAC	CTA	GTC	TTA	AAG	CAG	ACA	TCC	TCC	ATC	CCT	
		740			750			760			770			780				
	257	M	M	R	S	E	I	Q	Q	L	K	T	S	V	A	V	M	272
		ATG	ATG	CGG	TCT	GAA	ATC	CAA	CAG	CTA	AAA	ACA	TCT	GTT	GCG	GTC	ATG	
		790			800			810			820			830				
50	273	E	A	N	L	G	M	M	K	I	L	D	P	G	C	A	N	288
		GAA	GCT	AAT	TTA	GGC	ATG	ATG	AAA	ATT	CTG	GAC	CCT	GGT	TGT	GCT	AAC	
		840			850			860			870			880				
	289	I	S	S	L	S	D	L	R	A	V	A	R	S	H	P	V	304
		ATT	TCA	TCC	TTA	AGT	GAT	CTG	CGG	GCA	GTC	GCC	CGG	TCC	CAC	CCA	GTT	
		890			900			910			920			930				

305 L I S G P G D P S P Y V T Q G G 320
 TTA ATT TCA GGC CCC GGA GAT CCG TCC CCC TAC GTG ACA CAA GGG GGT
 920 930 940 950 960
 5 321 E M T L N K L S Q P V Q H P S E 336
 GAG ATG ACA CTC AAT AAA CTC TCA CAA CCA GTA CAA CAC CCT TCC GAG
 970 980 990 1000
 337 L I K S A T A G G P D M G V E K 352
 TTA ATT AAA TCT GCC ACA GCG GGC GGA CCT GAT ATG GGA GTG GAA AAG
 1010 1020 1030 1040 1050
 10 353 D T V R A L I T S R P M H P S S 368
 GAC ACT GTC CGT GCA TTG ATC ACC TCG CGC CCG ATG CAT CCA AGC TCC
 1060 1070 1080 1090 1100
 369 S A K L L S K L D A A G S I E E 384
 TCA GCT AAG CTC CTG AGT AAG CTG GAT GCA GCC GGG TCG ATT GAA GAG
 1110 1120 1130 1140 1150
 15 385 I R K I K R L A L N G * 396
 ATC AGA AAG ATC AAG CGC CTT GCA CTA AAT GGC TAA
 1160 1170 1180

- 20 7. A recombinant expression plasmid containing the NDV nucleocapsid gene as claimed in claim 1 or claim 2.
8. A recombinant expression plasmid containing the NDV phosphoprotein gene as claimed in claim 3 or claim 4.
- 25 9. The recombinant expression plasmid according to claim 7 which is the expression plasmid pTrcHis2-NP constructed by cloning the NDV nucleocapsid gene of claims 1 or 2 into vector pTrcHis2.
10. The recombinant expression plasmid according to claim 8 which is the expression plasmid pTrcHis2-P constructed by cloning the NDV phosphoprotein gene of claims 3 or 4 into vector pTrcHis2.
- 30 11. A transformed *Escherichia coli* with the recombinant expression plasmid according to claim 7 or claim 9.
12. A transformed *Escherichia coli* with the recombinant expression plasmid according to claim 8 or claim 10.

13. The transformed microorganism according to claim 11, which is the transformed *E. coli* TOP10 (pTrcHis2-NP) produced by introducing the recombinant expression plasmid of claim 7 or claim 9 into *E. coli* TOP10.

5 14. The transformed microorganism according to claim 12, which is the transformed *E. coli* (pTrcHis2-P) produced by introducing the recombinant expression plasmid of claim 8 or claim 10 into *E. coli* TOP 10.

15. A fused or non-fused form of NDV nucleocapsid protein isolated and purified from culture of the transformed microorganism of claim 11 or claim 13 characterised in that it has the following amino acid sequence:

10	1	M	S	S	V	F	D	E	Y	E	Q	L	L	A	A	Q	T	16
		ATG	TCT	TCC	GTA	TTC	GAT	GAA	TAC	GAG	CAG	CTC	CTC	GCT	GCT	CAG	ACT	
		1			10			20			30			40				
	17	R	P	N	G	A	H	G	G	G	E	R	G	S	T	L	R	32
15		CGC	CCC	AAT	GGA	GCT	CAC	GGA	GGG	GGA	GAG	AGA	GGG	AGC	ACT	TTA	AGA	
		50			60			70			80			90				
	33	V	E	V	P	V	F	T	L	N	S	D	D	P	E	D	R	48
		GTT	GAG	GTC	CCA	GTA	TTC	ACT	CTT	AAC	AGT	GAC	GAT	CCA	GAA	GAT	AGA	
		100			110			120			130			140				
20	49	W	N	F	A	V	F	C	L	R	I	A	V	S	E	D	A	64
		TGG	AAT	TTT	GCG	GTA	TTC	TGT	CTT	CGG	ATT	GCT	GTT	AGC	GAG	GAC	GCC	
		150			160			170			180			190				
	65	N	K	P	L	R	Q	G	A	L	I	S	L	L	C	S	H	80
		AAC	AAA	CCG	CTC	AGG	CAA	GGT	GCT	CTC	ATA	TCC	CTC	CTG	TGC	TCC	CAT	
			200			210			220			230			240			
25	81	S	Q	V	M	R	N	H	V	A	L	A	G	K	Q	N	E	96
		TCT	CAA	GTG	ATG	AGG	AAC	CAT	GTT	GCC	CTT	GCA	GGA	AAA	CAG	AAT	GAG	
			250			260			270			280						
	97	A	T	L	T	V	L	E	I	D	G	F	T	S	S	V	P	112
30		GCT	ACA	CTG	ACT	GTT	CTT	GAG	ATC	GAT	GGT	TTT	ACC	AGC	AGC	GTG	CCT	
		290			300			310			320			330				
	113	Q	F	N	N	R	S	G	V	S	E	E	R	A	Q	R	F	128
		CAG	TTC	AAC	AAC	AGG	AGT	GGG	GTG	TCT	GAG	GAG	AGA	GCA	CAG	AGA	TTC	
		340			350			360			370			380				
	129	M	V	I	A	G	S	L	P	R	A	C	S	N	G	T	P	144
35		ATG	GTG	ATA	GCA	GGG	TCT	CTC	CCT	CGG	GCG	TGC	AGT	AAC	GGT	ACT	CCG	
		390			400			410			420			430				
	145	F	V	T	A	G	V	E	D	D	A	P	E	D	I	T	D	160
		TTC	GTC	ACG	GCT	GGG	GTT	GAA	GAT	GAT	GCA	CCA	GAA	GAT	ATC	ACT	GAT	
			440			450			460			470			480			
40	161	T	L	E	R	I	L	S	I	Q	A	Q	V	W	V	T	V	176
		ACT	CTG	GAA	AGA	ATC	CTG	TCT	ATC	CAG	GCT	CAG	GTA	TGG	GTC	ACA	GTA	
			490			500			510			520						

	177	A	K	A	M	T	A	Y	E	T	A	D	E	S	E	T	R	192
		GCG	AAG	GCC	ATG	ACT	GCA	TAT	GAG	ACA	GCA	GAT	GAG	TCG	GAA	ACA	AGA	
		530			540			550			560			570				
5	193	R	I	N	K	Y	M	Q	Q	G	R	V	Q	K	K	Y	I	208
		ACA	ATC	AAT	AAG	TAC	ATG	CAG	CAA	GGC	AGA	GTC	CAG	AAG	AAG	TAC	ATC	
		580			590			600			610			620				
	209	L	H	P	V	C	R	S	A	I	Q	L	T	I	R	H	S	224
		CTC	CAC	CCT	GTA	TGC	AGG	AGT	GCA	ATT	CAA	CTC	ACA	ATC	AGA	CAT	TCT	
		630			640			650			660			670				
10	225	L	A	V	R	I	F	L	V	S	E	L	K	R	G	R	N	240
		CTG	GCA	GTC	CGC	ATT	TTC	TTA	GTT	AGC	GAG	CTT	AAG	AGA	GGC	CGC	AAT	
		680			690			700			710			720				
	241	T	A	G	G	S	S	T	Y	Y	N	L	V	G	D	V	D	256
		ACG	GCA	GGT	GGG	AGC	TCC	ACG	TAT	TAC	AAC	TTA	GTA	GGG	GAT	GTA	GAC	
15				730			740			750			760					
	257	S	Y	I	R	N	T	G	L	T	A	F	F	L	T	L	K	272
		TCA	TAC	ATC	AGG	AAC	ACC	GGA	CTT	ACT	GCA	TTC	TTC	CTT	ACA	CTC	AAA	
		770			780			790			800			810				
20	273	Y	G	I	N	T	K	T	S	A	L	A	L	S	S	L	T	288
		TAT	GGA	ATT	AAT	ACC	AAG	ACA	TCA	GCC	CTA	GCA	CTC	AGC	AGC	CTC	ACA	
		820			830			840			850			860				
	289	G	D	I	Q	K	M	K	Q	L	M	R	L	Y	R	M	K	304
		GGC	GAT	ATC	CAA	AAG	ATG	AAG	CAG	CTC	ATG	CGT	TTA	TAT	CGG	ATG	AAG	
		870			880			890			900			910				
25	305	G	E	N	A	P	Y	M	T	L	L	G	D	S	D	Q	M	320
		GGA	GAA	AAT	GCG	CCG	TAC	ATG	ACA	TTG	CTA	GGT	GAC	AGT	GAT	CAG	ATG	
		920			930			940			950			960				
	321	S	F	A	P	A	E	Y	A	Q	L	Y	S	F	A	M	G	336
		AGC	TTT	GCA	CCG	GCT	GAG	TAT	GCA	CAG	CTT	TAT	TCT	TTT	GCC	ATG	GGC	
30				970			980			990			1000					
	337	M	A	S	V	L	D	K	G	T	G	K	Y	Q	F	A	R	352
		ATG	GCA	TCA	GTC	TTA	GAT	AAA	GGA	ACT	GGC	AAA	TAC	CAA	TTC	GCC	AGA	
		1010		1020			1030			1040			1050					
35	353	D	F	M	S	T	S	F	W	R	L	G	V	E	Y	A	Q	368
		GAC	TTC	ATG	AGC	ACA	TCA	TTC	TGG	AGA	CTC	GGG	GTG	GAG	TAT	GCT	CAG	
		1060			1070			1080			1090			1100				
	369	A	Q	G	S	S	I	N	E	D	M	A	A	E	L	K	L	384
		GCT	CAG	GGG	AGT	AGC	ATC	AAC	GAA	GAC	ATG	GCT	GCT	GAG	CTA	AAA	CTA	
		1110			1120			1130			1140			1150				
40	385	T	P	A	A	R	R	G	L	A	A	A	A	Q	R	V	S	400
		ACC	CCG	GCA	GCA	AGA	AGG	GGC	CTG	GCA	GCT	GCT	GCC	CAA	CGA	GTG	TCT	
		1160			1170			1180			1190			1200				
	401	E	E	T	G	S	V	D	I	P	T	Q	Q	A	G	V	L	416
		GAG	GAA	ACT	GGC	AGC	GTG	GAT	ATT	CCT	ACT	CAA	CAA	GCC	GGG	GTC	CTC	
45				1210			1220			1230			1240					
	417	T	G	L	S	D	G	G	P	R	A	S	Q	G	G	S	N	432
		ACT	GGG	CTC	AGC	GAT	GGA	GGC	CCC	CGA	GCC	TCT	CAG	GGT	GGA	TCG	AAC	
		1250			1260			1270			1280			1290				
50	433	K	S	Q	G	Q	P	D	A	G	D	G	E	T	Q	F	L	448
		AAG	TCG	CAA	GGG	CAA	CCA	GAT	GCC	GGA	GAT	GGG	GAG	ACC	CAA	TTC	TTG	
		1300			1310			1320			1330			1340				

449 D L M R A V A N S M R E A P N S 464
 GAT TTG ATG AGA GCA GTG GCG AAC AGC ATG CGA GAA GCG CCA AAC TCC
 1350 1360 1370 1380 1390
 5 465 A Q S T T H P E P P P T P G P S 480
 GCA CAG AGC ACC ACC CAC CCG GAA CCC CCC CCG ACT CCC GGG CCA TCC
 1400 1410 1420 1430 1440
 481 Q D N D T D W G Y * 490
 CAA GAT AAC GAC ACC GAC TGG GGG TAT TGA
 1450 1460 1470

10 16. A fused or non-fused form of NDV phosphoprotein isolated and purified from
 culture of the transformed microorganism of claim 12 or claim 14
 characterised in that it has the following amino acid sequence:


15 1 M A T F T D A E I D D I F E T S 16
 ATG GCC ACC TTT ACA GAT GCG GAG ATA GAT GAT ATA TTT GAG ACC AGT
 1 10 20 30 40
 17 G T V I D S I I T A Q G K S A E 32
 GGA ACT GTC ATT GAC AGC ATA ATT ACG GCC CAG GGT AAA TCA GCA GAG
 50 60 70 80 90
 20 33 T V G R S A I P Q G K T K A L S 48
 ACT GTC GGA AGG AGC GCA ATC CCA CAA GGC AAG ACC AAA GCG CTG AGC
 100 110 120 130 140
 49 I A W E K H G S I Q P S T S Q D 64
 ATA GCA TGG GAG AAG CAT GGG AGC ATC CAA CCA TCC ACC AGC CAG GAC
 150 160 170 180 190
 25 65 N P D Q Q D R P D K Q L S T P E 80
 AAC CCC GAC CAA CAG GAT AGA CCA GAC AAA CAG CTA TCC ACA CCT GAG
 200 210 220 230 240
 30 81 Q A T P H N S S P A T S A E P L 96
 CAG GCG ACC CCA CAC AAC AGC TCG CCA GCC ACA TCC GCC GAA CCG CTC
 250 260 270 280
 97 P T Q A A G E A G D T Q L K T G 112
 CCC ACT CAG GCC GCA GGT GAG GCC GGC GAC ACA CAG CTC AAG ACC GGA
 290 300 310 320 330
 35 113 A S N S L L S M L D K L S N K P 128
 GCA AGC AAC TCT CTT CTG TCT ATG CTC GAC AAG CTG AGC AAT AAA CCA
 340 350 360 370 380
 129 S N A K K G P W S S P Q E G Y H 144
 TCT AAT GCT AAA AAG GGC CCA TGG TCG AGT CCC CAG GAA GGA TAT CAT
 390 400 410 420 430
 40 145 Q P P T Q Q H G D Q P N R G N S 160
 CAA CCT CCG ACC CAA CAA CAT GGG GAT CAG CCG AAC CGC GGA AAC AGC
 440 450 460 470 480
 161 Q E R L R H Q A K A A P G S R G 176
 CAG GAG AGG CTG CGG CAC CAA GCC AAG GCC GCC CCT GGA AGC CGG GGC
 490 500 510 520

5	177	T	D	A	S	T	A	Y	H	G	Q	W	K	E	S	Q	L	192
		ACA	GAC	GCG	AGC	ACA	GCA	TAT	CAT	GGA	CAA	TGG	AAG	GAG	TCA	CAA	CTA	
		530			540			550			560			570				
10	193	S	A	G	A	T	P	H	V	L	Q	S	G	Q	S	Q	D	208
		TCA	GCT	GGT	GCA	ACC	CCT	CAT	GTG	CTC	CAA	TCA	GGG	CAG	AGC	CAA	GAC	
		580			590			600			610			620				
15	209	S	T	P	V	P	V	D	H	V	Q	P	P	V	D	F	V	224
		AGT	ACT	CCT	GTA	CCT	GTG	GAT	CAT	GTC	CAG	CCA	CCT	GTC	GAC	TTT	GTG	
		630			640			650			660			670				
20	225	Q	A	M	M	T	M	M	E	A	L	S	Q	K	V	S	K	240
		CAG	GCG	ATG	ATG	ACT	ATG	ATG	GAG	GCG	TTA	TCA	CAG	AAG	GTA	AGT	AAA	
		680			690			700			710			720				
25	241	V	D	Y	Q	L	D	L	V	L	K	Q	T	S	S	I	P	256
		GTC	GAC	TAT	CAG	CTA	GAC	CTA	GTC	TTA	AAG	CAG	ACA	TCC	TCC	ATC	CCT	
		730			740			750			760			770				
30	257	M	M	R	S	E	I	Q	Q	L	K	T	S	V	A	V	M	272
		ATG	ATG	CGG	TCT	GAA	ATC	CAA	CAG	CTA	AAA	ACA	TCT	GTT	GCG	GTC	ATG	
		770			780			790			800			810				
35	273	E	A	N	L	G	M	M	K	I	L	D	P	G	C	A	N	288
		GAA	GCT	AAT	TTA	GGC	ATG	ATG	AAA	ATT	CTG	GAC	CCT	GGT	TGT	GCT	AAC	
		820			830			840			850			860				
40	289	I	S	S	L	S	D	L	R	A	V	A	R	S	H	P	V	304
		ATT	TCA	TCC	TTA	AGT	GAT	CTG	CGG	GCA	GTC	GCC	CGG	TCC	CAC	CCA	GTT	
		870			880			890			900			910				
45	305	L	I	S	G	P	G	D	P	S	P	Y	V	T	Q	G	G	320
		TTA	ATT	TCA	GGC	CCC	GGA	GAT	CCG	TCC	CCC	TAC	GTG	ACA	CAA	GGG	GGT	
		920			930			940			950			960				
50	321	E	M	T	L	N	K	L	S	Q	P	V	Q	H	P	S	E	336
		GAG	ATG	ACA	CTC	AAT	AAA	CTC	TCA	CAA	CCA	GTA	CAA	CAC	CCT	TCC	GAG	
		970			980			990			1000			1010				
55	337	L	I	K	S	A	T	A	G	G	P	D	M	G	V	E	K	352
		TTA	ATT	AAA	TCT	GCC	ACA	GCG	GGC	GGA	CCT	GAT	ATG	GGA	GTG	GAA	AAG	
		1010			1020			1030			1040			1050				
60	353	D	T	V	R	A	L	I	T	S	R	P	M	H	P	S	S	368
		GAC	ACT	GTC	CGT	GCA	TTG	ATC	ACC	TCG	CGC	CCG	ATG	CAT	CCA	AGC	TCC	
		1060			1070			1080			1090			1100				
65	369	S	A	K	L	L	S	K	L	D	A	A	G	S	I	E	E	384
		TCA	GCT	AAG	CTC	CTG	AGT	AAG	CTG	GAT	GCA	GCC	GGG	TCG	ATT	GAA	GAG	
		1110</																

ABSTRACT

Nucleotide Sequences of the Nucleocapsid (NP) and Phosphoprotein (P) Genes of a Malaysian Velogenic Newcastle Disease Virus Strain AF2240 and the Production of the NP and P Proteins in *Escherichia coli*

- 5 The present invention relates to nucleotide sequences encoding the nucleocapsid (NP) protein and phosphoprotein (P) of Newcastle disease virus (NDV) and the production of the corresponding proteins with recombinant plasmids bearing the nucleotide sequences in *Escherichia coli*.



Detection of NP protein with anti-NDV chicken serum

lanes:


1: Molecular mass standards expressed in kDa

2 & 3: NP fusion protein

4 & 5: NP non-fusion protein

6: NDV


Figure 1



Detection of P fusion protein with the anti-*Myc* monoclonal antibody

lanes:

- 1: Cells containing the recombinant P fusion plasmid after being induced with IPTG for 5 h
- 2: Cells containing the recombinant P fusion plasmid after being induced with IPTG for 3 h
- 3: Cells containing the recombinant P fusion plasmid after being induced with IPTG for 1 h
- 4: Cells containing the recombinant P fusion plasmid **before being induced with IPTG**
- 5: Cells harbouring empty vector
- 6: Molecular mass standards expressed in kDa



Detection of P non-fusion protein with anti-NDV chicken serum

lanes:

- 1: Molecular mass standards expressed in kDa
- 2: Cells harbouring empty vector
- 3: Cells containing the recombinant P non-fusion plasmid **before being induced with IPTG**
- 4: Cells containing the recombinant P non-fusion plasmid after being induced with IPTG for 2 h
- 5: Cells containing the recombinant P non-fusion plasmid after being induced with IPTG for 4 h
- 6: Cells containing the recombinant P non-fusion plasmid after being induced with IPTG for 6 h

Figure 2